Also known as: Imbruvica
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor marketed as Imbruvica. It is used for B-cell malignancies such as chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenström macroglobulinemia, and also for chronic graft-versus-host disease. The FDA first approved it on November 13, 2013.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Johnson & Johnson raised its full-year forecast after stronger-than-expected quarterly results driven by cancer, immunology and neuroscience drugs. Sales were $24.56 billion and adjusted earnings were $2.46 per share, with Innovative Medicines sales rising 10.0% to $15.76 billion.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
Pharmac has proposed expanding access to melanoma treatments and funding two new therapies for chronic lymphocytic leukaemia. Medical researchers also highlight that New Zealanders lack access to CAR T-cell therapy domestically.
Retrospective analysis of the ZUMA-2 trial found that previous ibrutinib exposure was associated with improved progression-free survival after brexucabtagene autoleucel treatment in mantle cell lymphoma patients, though with increased toxicity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07377578 |
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma |
RECRUITING | PHASE3 |
| NCT07169565 |
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia |
NOT_YET_RECRUITING | PHASE1 |
| NCT07082868 |
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) |
RECRUITING | PHASE1 |
| NCT07052695 |
Mosunetuzumab for CLL MRD Clearance |
RECRUITING | PHASE1/PHASE2 |
| NCT06649812 |
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma |
RECRUITING | PHASE2 |
| NCT06536049 |
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT06482684 |
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma |
RECRUITING | PHASE2 |
| NCT06357676 |
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial |
RECRUITING | PHASE1/PHASE2 |
| NCT06299540 |
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia |
RECRUITING | |
| NCT06271616 |
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant |
TERMINATED | PHASE2 |
